Caldas C, Ambinder R
Johns Hopkins Oncology Center, Baltimore, Maryland, USA.
Curr Opin Oncol. 1995 Mar;7(2):102-6. doi: 10.1097/00001622-199503000-00002.
The development of Epstein-Barr virus-associated posttransplantation lymphoproliferative disease correlates with increased viral burden in lymphocytes. Patterns of viral gene expression in tumors are complex and heterogenous. Conventional chemotherapy for postransplantation lymphoproliferative disease is sometimes associated with long-term disease-free survival. A promising new approach involves adoptive cellular immunotherapy with donor lymphocytes or T-cell lines. Allogeneic bone marrow transplantation has been successful in patients with an inherited lack of immune response to Epstein-Barr virus.
爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增生性疾病的发展与淋巴细胞中病毒载量增加相关。肿瘤中病毒基因表达模式复杂且异质性强。移植后淋巴细胞增生性疾病的传统化疗有时与长期无病生存相关。一种有前景的新方法涉及用供体淋巴细胞或T细胞系进行过继性细胞免疫治疗。对于遗传性缺乏对爱泼斯坦-巴尔病毒免疫反应的患者，异基因骨髓移植已取得成功。
